Taysha Gene Therapies (TSHA) Net Cash Flow (2020 - 2026)

Taysha Gene Therapies has disclosed Net Cash Flow across 7 years of filings, most recently posting -$43.2 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$43.2 million, down 92.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.1 million (up 2267.96% YoY), and the FY2025 annual result was $180.9 million, up 3788.72% from the prior year.
• Net Cash Flow came in at -$43.2 million for Q1 2026 at Taysha Gene Therapies, down from $22.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $196.2 million in Q2 2025 to a low of -$52.5 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$18.7 million (2024), against an average of $7.5 million.
• Peak annual rise in Net Cash Flow reached 473.27% in 2023, while the deepest fall reached 138.03% in 2023.
• Taysha Gene Therapies' Net Cash Flow stood at $53.6 million in 2022, then slumped by 138.03% to -$20.4 million in 2023, then gained by 8.46% to -$18.7 million in 2024, then surged by 221.1% to $22.6 million in 2025, then sank by 291.22% to -$43.2 million in 2026.
• The last three Net Cash Flow figures came in at -$43.2 million (Q1 2026), $22.6 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.